Corrigendum to “Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy” [Neuropharmacology 143 (2018) 186–204]
Brandt, Claudia, Seja, Patricia, Töllner, Kathrin, Römermann, Kerstin, Hampel, Philip, Kalesse, Markus, Kipper, Andi, Feit, Peter W., Lykke, Kasper, Toft-Bertelsen, Trine Lisberg, Paavilainen, PauliinLanguage:
english
Journal:
Neuropharmacology
DOI:
10.1016/j.neuropharm.2018.10.012
Date:
October, 2018
File:
PDF, 345 KB
english, 2018
File converter
More search results
More benefits 
